ASPIRIN AND DIPYRIDAMOLE by Novartis is extended-release dipyridamole capsules is the result of the additive antiplatelet effects of dipyridamole and aspirin. Approved for stroke in patients, completed ischemic stroke due to thrombosis, completed ischemic stroke due to thrombosis (). First approved in 2017.
Drug data last refreshed 3d ago
extended-release dipyridamole capsules is the result of the additive antiplatelet effects of dipyridamole and aspirin. Dipyridamole Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo ; the inhibition occurs in a dose-dependent…
Worked on ASPIRIN AND DIPYRIDAMOLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.